|
 
Peer Advisor: The Impact of Fibrate Therapy for Treating Dyslipidemias
Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit. 
Course Objectives: This CME-certified activity is intended for cardiologists, primary care physicians, and healthcare practitioners who treat patients with lipid disorders. Accreditation: These activities were reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Mark A. Gendreau, MD, MS, Nicole Weinreb, MD, Abigail Zavod, MD, Alexandra Mangili, MD, MPH, Paula Brathwaite, MD and Evan Teplow, MD.
Release Date: August 2008
Expiration Date: August 30, 2009
Millennium CME Institute, Inc., is accredited by the ACCME to provide continuing medical education for physicians. Millennium CME Institute, Inc., designates these CME-certified activities for a maximum total of 4.0 AMA PRA Category 1 Credits™. Participants should only claim credit commensurate with the extent of their participation in the activity.
© 2008 Millennium CME Institute, Inc. All rights reserved including translation into other languages. No part of this activity maybe reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Millennium CME Institute, Inc. Faculty Disclosure: Expert Commentary
Dean A. Bramlet, MD, FACC, FACP, FAHA, Diplomate of Clinical Lipidology, Assistant Consulting Professor of Medicine, Duke University; Medical Director, Cardiovascular Diagnostic Center of the Heart and Lipid Institute of Florida, St. Petersburg, Florida
Eliot A. Brinton, MD, Director, Metabolism Section, Cardiovascular Genetics, Associate Professor, University of Utah School of Medicine, Salt Lake City, Utah
Christopher P. Cannon, MD, Senior Investigator, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts
Sergio Fazio, MD, PhD, Professor of Medicine and Pathology, Co-Director, Atherosclerosis Research Unit, Vanderbilt University Medical Center, Nashville, Tennessee
Jeffery Boord, MD, MPH, Assistant Professor of Medicine, Quality Director, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee
Medical Reviewer
Mark A. Gendreau, MD, MS, Senior Staff Physician, Lahey Clinic, Burlington, Massachusetts
Planning Committee
Tim I. Robinson, President,
Millennium CME Institute, Inc., Hampton, New Hampshire
Frank A. Gesek, PhD, RPh, Clinical Affairs Specialist,
Millennium CME Institute, Inc., Hampton, New Hampshire
Peter B. Lindgren, PhD, Clinical Affairs Specialist,
Millennium CME Institute, Inc., Hampton, New Hampshire
Disclaimer
The opinions expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Abbott, any other manufacturer of pharmaceuticals, or Millennium CME Institute, Inc. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.
Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations
Millennium CME Institute, Inc., endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. All faculty are required to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations and with companies who have provided the commercial support for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
The faculty listed below have declared that they have no relationships to disclose:
Jeffery Boord, MD, MPH
Mark A. Gendreau, MD
Alexandra Mangili, MD, MPH
Paula Brathwaite, MD
Abigail Zavod, MD
Nicole Weinreb, MD
Evan Teplow, MD
Tim I. Robinson
Frank A. Gesek, PhD, RPh
Peter B. Lindgren, PhD
The faculty listed below have declared the following arrangements and/or affiliations:
Dean A. Bramlet, MD, FACC, FACP, FAHA: Speaker: Abbott, Astra Zeneca, Merck, Schering-Plough, Sankyo
Sergio Fazio, MD, PhD: Speaker: Abbott, Merck, Glaxo Smith Klein, Schering-Plough
Christopher Cannon, MD: Grant/Research: Accumetrics, Astra Zeneca, Bristol-Meyers Squibb, Glaxo Smith Klein, Merck, Sanofi-Aventis, Schering Plough
Eliot A. Brinton, MD: Consultant: Astra-Zeneca; Speaker/Consultant: Glaxo Smith Klein, Takeda; Speaker/Consultant/Researcher: Abbott Directions: The participant should read the learning objectives and review the activity in its entirety. After reviewing the material, the participant should complete the Activity Self-assessment Test consisting of a series of multiple-choice questions.
Upon successfully completing this activity as designed and achieving a passing score of 70% or higher on the Activity Self-assessment Test, participants will receive a continuing education credit letter awarding the appropriate credit and the Activity Self-assessment Test answers four to six weeks after the receipt of the registration and evaluation materials. CME Testing Options
   
|